CHRNE

Across TCGA pan-cancer cohorts, CHRNE RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CHRNE’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CHRNE RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CHRNE is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRC, KICH, and THCA are the cancer types where CHRNE tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHRNE RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.732	<.001	12	view →
KICH	All	II,III,IV	−0.930	<.001	9	view →
THCA	Male	All	+0.482	<.001	5	view →
BRCA	All	II,III,IV	−0.312	<.001	4	view →
COAD	Male	III,IV	+0.223	.007	2	view →
PRAD	All	All	−0.152	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CHRNE–KIRC

Open the KIRC breakdown →